BioAge Labs (NASDAQ:BIOA) Sets New 52-Week High – Here’s What Happened

BioAge Labs, Inc. (NASDAQ:BIOA) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $16.85 and last traded at $16.0640, with a volume of 317585 shares changing hands. The stock had previously closed at $14.03.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Citigroup upped their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Finally, Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioAge Labs presently has an average rating of “Hold” and an average price target of $15.00.

BioAge Labs Stock Up 23.2%

The firm has a market capitalization of $619.85 million, a PE ratio of -11.53 and a beta of 1.38. The company’s 50-day simple moving average is $10.90.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Insider Activity

In other news, insider Paul D. Rubin sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total value of $216,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.82% of the company’s stock.

Institutional Trading of BioAge Labs

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after buying an additional 93,694 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Millennium Management LLC grew its holdings in shares of BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after purchasing an additional 270,479 shares in the last quarter. Marshall Wace LLP increased its position in shares of BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after purchasing an additional 173,388 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its stake in BioAge Labs by 202.2% in the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.